245 related articles for article (PubMed ID: 2494599)
21. Renal bone disease in patients on haemodialysis: biochemical and radiological assessment.
Lye WC; Lee EJ
Ann Acad Med Singap; 1992 Nov; 21(6):760-4. PubMed ID: 1295414
[TBL] [Abstract][Full Text] [Related]
22. [The role of aluminum in the human body].
Strzałkowska D
Postepy Hig Med Dosw; 1991; 45(3-4):257-79. PubMed ID: 1946095
[TBL] [Abstract][Full Text] [Related]
23. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
[TBL] [Abstract][Full Text] [Related]
24. [Prevalence of histological types of bone disease in a hemodialysis center limiting the oral intake of aluminum hydroxide].
Belbrik S; Marie A; Boudailliez B; Morinière P; Sébert JL; Solal MC; Westeel PF; Roche D; Fournier A
Nephrologie; 1990; 11(2):83-90. PubMed ID: 2392208
[TBL] [Abstract][Full Text] [Related]
25. Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure.
Biswas CK; Arze RS; Ramos JM; Ward MK; Dewar JH; Kerr DN; Kenward DH
Br Med J (Clin Res Ed); 1982 Mar; 284(6318):776-8. PubMed ID: 6802224
[TBL] [Abstract][Full Text] [Related]
26. Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.
Ellis HA; McCarthy JH; Herrington J
J Clin Pathol; 1979 Aug; 32(8):832-44. PubMed ID: 389958
[TBL] [Abstract][Full Text] [Related]
27. Renal osteodystrophy in CAPD.
Hutchison AJ; Freemont AJ; Lumb GA; Gokal R
Adv Perit Dial; 1991; 7():237-9. PubMed ID: 1680434
[TBL] [Abstract][Full Text] [Related]
28. Aluminium load in patients with analgesic nephropathy.
Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G
Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045
[TBL] [Abstract][Full Text] [Related]
29. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
[TBL] [Abstract][Full Text] [Related]
30. Serum aluminium level in the veneto chronic haemodialysis population: cross-sectional study on 1,026 patients.
Piccoli A; Andriani M; Mattiello G; Nordio M; Modena F; Dalla Rosa C
Nephron; 1989; 51(4):482-90. PubMed ID: 2787000
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
32. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
[TBL] [Abstract][Full Text] [Related]
33. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
Salusky IB; Foley J; Nelson P; Goodman WG
N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
[TBL] [Abstract][Full Text] [Related]
34. Value of serum aluminium monitoring in dialysis patients: a multicentre study.
D'Haese PC; Clement JP; Elseviers MM; Lamberts LV; Van de Vyver FL; Visser WJ; De Broe ME
Nephrol Dial Transplant; 1990; 5(1):45-53. PubMed ID: 2109284
[TBL] [Abstract][Full Text] [Related]
35. Aluminum and renal osteodystrophy in chronic uremia.
Berland Y; Grandvuillemin M; Charhon S; Olmer M
Kidney Int Suppl; 1985 Dec; 17():S183-7. PubMed ID: 3867793
[No Abstract] [Full Text] [Related]
36. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
[TBL] [Abstract][Full Text] [Related]
37. Treatment of fracturing renal osteodystrophy by desferrioxamine.
Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
[TBL] [Abstract][Full Text] [Related]
38. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
[TBL] [Abstract][Full Text] [Related]
39. Effect of phosphate binging agents on bone remodelling in patients on regular haemodialysis.
Fournier A; Tunchot S; Bedrossian J; Sionest JG; Idatte JM; Bordier P
Proc Eur Dial Transplant Assoc; 1972; 9():126-41. PubMed ID: 4668905
[No Abstract] [Full Text] [Related]
40. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
Wallace MR; Pybus J
N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
